Impact of physicians' awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC). - Morgans, Alicia K.; Touya, Maelys; El-Chaar, Nader N.; Elsouda, Dina; Ramaswamy, Krishnan; Adejumo, Kelechi L.; Gentile, Danielle; Feinberg, Bruce A.; Asgarisabet, Parisa; Pathak, Prathamesh; Freedland, Stephen J. (Journal of Clinical Oncology)